Brief: ProPhase Lab Unveils Substantial Expansion Strategy For Pharmaloz Manufacturing

Prophase Labs

17/10/2023 14:43

Oct 17 (Reuters) - Prophase Labs Inc  PRPH.O :
    * PROPHASE LABS INC - PHARMALOZ PLAN IS TO BUILD CAPACITY
WITH A
GOAL TO ATTAIN A REVENUE RUN-RATE OF $60 TO $80 MILLION BY
YEAR-END 2024
    * PROPHASE LABS - PHARMALOZ IS PROJECTED TO ACHIEVE A
RUN-RATE OF
$15 MILLION IN ANNUALIZED REVENUES & RUN-RATE OF $3+ MILLION IN
GROSS PROFIT DURING Q1 2024
    * PROPHASE LABS INC - UNVEILED SUBSTANTIAL EXPANSION
STRATEGY FOR
ITS WHOLLY-OWNED SUBSIDIARY, PHARMALOZ MANUFACTURING, INC.
    * PROPHASE LABS- EQUIPMENT FOR A SECOND LOZENGE
MANUFACTURING LINE
HAS ALREADY BEEN ORDERED AT PHARMALOZ, WITH DELIVERY,
INSTALLATION PLANNED FOR Q2 2024

Source text for Eikon:  ID:nGNX1jwFqq 
Further company coverage:  PRPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))